Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Position Increased by Nissay Asset Management Corp Japan ADV

Nissay Asset Management Corp Japan ADV grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.6% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 24,125 shares of the biopharmaceutical company's stock after buying an additional 847 shares during the period. Nissay Asset Management Corp Japan ADV's holdings in Regeneron Pharmaceuticals were worth $17,187,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Rakuten Securities Inc. lifted its holdings in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $28,000. Avalon Trust Co bought a new stake in Regeneron Pharmaceuticals during the fourth quarter worth $36,000. Crowley Wealth Management Inc. acquired a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC raised its holdings in Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 39 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research reports. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. The Goldman Sachs Group cut their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 target price for the company. Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a report on Wednesday, April 30th. Finally, Bank of America reduced their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $890.60.

Regeneron Pharmaceuticals Stock Up 1.6%

REGN traded up $9.77 during trading hours on Tuesday, hitting $605.43. 349,112 shares of the company's stock were exchanged, compared to its average volume of 787,772. The firm has a market cap of $65.37 billion, a P/E ratio of 15.81, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $598.10 and a 200 day moving average of $680.17.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the prior year, the company earned $9.55 earnings per share. The firm's revenue was down 3.7% on a year-over-year basis. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a dividend of $0.88 per share. The ex-dividend date is Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.